Genvor Inc. to Present at the Life Sciences Virtual Investor Forum
Genvor, Inc. (OTCQB: GNVR), an innovator in AI-accelerated peptide technology for sustainable agriculture, is set to make a significant mark at the Life Sciences Virtual Investor Forum. On December 11, the company's CEO, Chad Pawlak, will deliver a live presentation that invites real-time interaction with investors.
Event Details
The virtual event will commence at 12:30 pm ET. Investors can expect an engaging session, complete with opportunities to ask questions during the presentation, ensuring a dynamic dialogue between Genvor's leadership and the investing community. For those unable to participate live, a recorded version will be accessible after the event.
Pre-Registration and Event Preparation
To enhance the experience, Genvor encourages potential attendees to pre-register and conduct a system check online, ensuring seamless participation while receiving timely event updates.
Recent Advancements by Genvor Inc.
Genvor has been making waves with impressive advancements in its operations:
- The company boasts five issued U.S. patents with two pending applications and plans for four more, alongside international filings in Canada, Mexico, and China. This strong intellectual property position fortifies their innovative peptide technologies, catering to antimicrobial, nutrient-enhancing, and insecticidal needs.
- Active trading on OTCQB resumed on October 9, 2025, propelling the company towards accelerated capital formation. This newly established financial framework is pivotal as Genvor expands its field trials and commercialization efforts globally.
- A new operational laboratory has been established in Woodland, California. This facility will bolster research and development for foliar and peptide-based formulations, enhancing Genvor's scientific capabilities and fostering further innovation in sustainable agriculture.
About Genvor Inc.
Genvor Inc. (OTCQB: GNVR) is at the forefront of sustainable agricultural innovations with its proprietary AI-accelerated peptide design platform. This technology translates single discoveries into broad multi-crop protection opportunities across diverse farming environments. By utilizing its unique BioCypher Algorithm—an intersection of computational biology and machine learning—Genvor is redefining what is possible in agricultural optimization with a focus on biological safety. The company is actively developing transformative peptides that offer Significant licensing opportunities for integration into existing agricultural practices.
About the Life Sciences Virtual Investor Forum
The Life Sciences Virtual Investor Forum is a unique platform that connects publicly traded companies with investors in a live, interactive setting. This event aims to replicate the experiences of an in-person investor conference while enhancing accessibility and engagement through real-time interactions and presentations.
CONTACTS:
Investor Relations
Genvor Incorporated
investors@genvor.com
Media
Carly Scaduto
carly@carlyscadutoconsulting.com
Frequently Asked Questions
What is the date of Genvor's presentation at the forum?
Genvor's presentation is scheduled for December 11, at 12:30 pm ET.
How can investors participate in the presentation?
Investors can participate by pre-registering for the event and are invited to ask questions during the live presentation.
What recent achievements has Genvor accomplished?
Genvor has secured five U.S. patents, resumed trading on OTCQB, and opened a new laboratory for R&D in sustainable agriculture.
What is the focus of Genvor's technology?
Genvor focuses on AI-accelerated peptide technology aimed at optimizing agricultural outcomes while ensuring biological safety.
How can I learn more about Genvor?
Additional information about Genvor is available on their official website at www.genvor.com.
